Welcome to nudaPETides. Coming soon.

The prescribing platform for veterinary peptide medicine. For licensed veterinarians.

Formulary
MetabolicDog. CatTier C

AOD-9604

Growth hormone fragment 176-191. Lipolysis without IGF-1 elevation. Body composition adjunct.

Weight

1,815 Da

Half-life

Under 30 minutes

Chain

15 amino acids

Studies

10 referenced. Latest 2023.

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library. Request access.

Overview

AOD-9604 is a 15-amino acid fragment of the C-terminus of human growth hormone. It carries the lipolytic action of GH without the growth and metabolic downstream effects. No IGF-1 elevation. No blood glucose disruption.

For patients where medically indicated weight loss is a real clinical goal.

Mechanism of action

  1. 01Activates lipolysis in adipocytes via beta-3 adrenergic pathways.
  2. 02Inhibits lipogenesis in adipose tissue.
  3. 03Preserves lean muscle mass during weight loss.
  4. 04Does not stimulate IGF-1 production.
  5. 05Does not affect glucose homeostasis or insulin sensitivity.

Molecular data

PropertyValue
Molecular weight1,815 Da
Chain length15 amino acids
TypehGH C-terminus fragment
RouteSubcutaneous

Species applicability

Dog

Obesity where lifestyle interventions have failed. Metabolic syndrome adjunct.

Cat

Emerging use in obese cats. Species differences in adipose biology require careful monitoring.

Prescribing indications

MetabolicEMERGING

Obesity in dogs and cats where weight management alone is inadequate.

PreoperativeEMERGING

Preoperative weight reduction under veterinary supervision.

Dosing framework

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

Reconstitution and administration

Full monograph, dosing tables, and prescribing rationale are available to verified veterinarians with an active license and documented VCPR workflow. Request access to unlock the complete formulary library.

Request access

What to expect

Week 2 to 4Early changes in body condition alongside diet and exercise.
Week 4 to 8Measurable body composition improvement in responsive patients.

Research library

Ng FM et al. Metabolic studies of a synthetic lipolytic domain of human growth hormone. Hormone Research.PubMedHeffernan MA et al. Effects of human GH and AOD9604 on lipid metabolism in obese mice. Endocrinology.PubMedBerryman DE et al. Effects of growth hormone on adipose tissue. Nature Reviews Endocrinology.PMC

Related peptides

NAD+

Longevity

View

Sermorelin

Endocrine

View

Glutathione

Hepatic

View

Regulatory footing

This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.

For licensed veterinarians only. Compounded under FDA GFI 256. Not FDA-approved.